Company Description
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally.
It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
The company’s other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-FcγRIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants.
The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C.
to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH.
CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People’s Republic of China.
| Country | China |
| Founded | 1991 |
| IPO Date | Jun 11, 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 176 |
| CEO | Wei-Wu He |
Contact Details
Address: 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road Beijing, 100025 China | |
| Phone | 86 10 6508 6063 |
| Website | casipharmaceuticals.com |
Stock Details
| Ticker Symbol | CASI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000895051 |
| CUSIP Number | 14757U208 |
| ISIN Number | US14757U2087 |
| Employer ID | 58-1959440 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Wei-Wu He Ph.D. | Chairman and Chief Executive Officer |
| Dr. Alexander A. Zukiwski M.D. | Executive Vice President and Chief Medical Officer |
| Dr. Wei Zhang Ph.D. | Senior Vice President |
| Dr. Daniel Lang M.D. | MD, Senior Vice President and Chief Financial Officer |
| Chunhua Wang | Chief Operating Officer |
| Wei Gao | General Counsel |
| Dr. James E. Goldschmidt Ph.D. | Chief Business Development Officer |
| Hai Huang | Global Chief Commercial Officer and GM of CASI China |
| Amanda Cui | Vice President and Global Controller |
| Kun Qian | Vice President and Global Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 24, 2023 | EFFECT | Notice of Effectiveness |
| Mar 22, 2023 | 15-12G | Securities registration termination |
| Mar 21, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 21, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 21, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 21, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 21, 2023 | POS AM | Post-Effective amendments for registration statement |
| Mar 21, 2023 | 8-K | Current Report |
| Feb 21, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |